Web-based delivery and digital migration of existing services
First written in FY2017-Q1. 9 of 16 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「Regarding generative AI, the Company is promoting active use in compliance with the rules while developing guidelines and ensuring that the associated risks are widely understood. In the Career business, a tool has been implemented that analyzes recordings of interviews between career consultants and job seekers and automatically generates interview feedback, contributing to greater accuracy in job recommendations.」
The digital transition initiative has progressed to the development of generative AI guidelines and implementation of a tool for analyzing interview data and automatically generating feedback. - FY2024-Q3AdvancedAnnual report
「In the overseas Medical Platform business, although the recovery in the use of non-digital products such as in-person events lengthened the lead time before revenue recognition, delivery progressed during the third quarter and performance remained steady.」
Although the recovery in the use of non-digital products lengthened the lead time before revenue recognition, delivery progressed during the third quarter and performance remained steady, according to the document. - FY2024-Q2Recovery in the use of non-digital productsAnnual report
「In the overseas Medical Platform business, first-half growth was limited because the recovery in the use of non-digital products, such as in-person events, lengthened the lead time before revenue could be recognized.」
In the Medical Platform business, use of non-digital products such as in-person events recovered alongside the existing digital products, but first-half growth was limited because of the longer lead time before revenue recognition. - FY2024-Q1AdvancedAnnual report
「The overseas Medical Platform business grew steadily as demand for digital products remained firm and use of non-digital products also recovered.」
As demand for digital products remained firm, use of non-digital products also recovered, contributing to growth overseas. Cumulative first-quarter sales overseas were ¥1,511 million, up 17.1% year on year. - FY2023RestatedAnnual report
「Under this policy, the Medical Platform business is advancing the provision of optimal marketing methods through a range of offline and online channels, while the Global Career business is expanding operations by increasing the number of countries in which it operates, with the aim of achieving strong growth across the overseas field.」
The use of both offline and online channels overseas and the policy of expanding the countries in which the Global Career business operates have been reaffirmed. - FY2023-Q3RestatedAnnual report
「The digital shift progressed amid the spread of COVID-19, and online events and digital products performed well.」
The digital shift overseas and the strong performance of online events and digital products have been reaffirmed. - FY2023-Q2RestatedAnnual report
「The digital shift progressed amid the spread of COVID-19, and online events and digital products performed well.」
The digital shift overseas and the strong performance of online events and digital products have been reaffirmed. - FY2023-Q1RestatedAnnual report
「The digital shift progressed amid the spread of COVID-19, and online events and digital products performed well.」
The digital shift overseas and the strong performance of online events and digital products have been reaffirmed. - FY2022-Q3RestatedAnnual report
「The digital shift progressed amid the spread of COVID-19, and online events and digital products performed well.」
The digital shift overseas and the strong performance of online events and digital products have been reaffirmed. - FY2022-Q1AdvancedAnnual report
「Overseas, the marketing support business for medical and healthcare-related companies grew significantly as the digital shift progressed amid the spread of COVID-19, while online events and digital products performed well. As a result, overseas sales for the cumulative first quarter were ¥1,031 million, up 24.8% year on year.」
The digital shift progressed in overseas marketing support, and strong performance by online events and digital products drove overseas sales up 24.8% year on year. - FY2021RestatedAnnual report
「In the marketing support business and other operations for medical and healthcare-related businesses, providing optimal marketing methods through a range of both offline and online channels」
The Web enablement and digital transition of existing services has been reaffirmed in terms of using both online and offline channels in overseas marketing support. - FY2021-Q3RestatedAnnual report
「Meanwhile, the digital shift progressed amid the impact of COVID-19, and online events and digital products performed well.」
The digital shift amid the impact of COVID-19 and the strong performance of online events and digital products have been reaffirmed. - FY2021-Q2AdvancedAnnual report
「Meanwhile, the digital shift progressed amid the impact of COVID-19, and online events and digital products performed well.」
The document states that, overseas, the digital shift progressed amid the impact of COVID-19, with online events and digital products performing well. - FY2017-Q3RestatedAnnual report
「In the mail-order business for nurses, sales fell below the year-earlier level following the shift from catalogs to the Web, but profit levels improved. In the existing businesses of the MIMS Group, initiatives are also being advanced to move the Pharma Marketing business to the Web.」
The initiative to move the mail-order business for nurses and MIMS’s Pharma Marketing business to the Web has been reaffirmed. - FY2017-Q2RestatedAnnual report
「In the mail-order business for nurses, sales fell below the year-earlier level following the shift from catalogs to the Web, but profit levels improved. In the existing businesses of the MIMS Group, initiatives are also being advanced to move the Pharma Marketing business to the Web.」
The initiative to move the mail-order business for nurses and MIMS’s Pharma Marketing business to the Web has been reaffirmed. - FY2017-Q1First statedAnnual report
「In the mail-order business for nurses, sales fell below the year-earlier level following the shift from catalogs to the Web, but profit levels improved. In the existing businesses of the MIMS Group, initiatives are also being advanced to move the Pharma Marketing business to the Web.」
Both the domestic mail-order business for nurses and MIMS’s Pharma Marketing business are progressing with the Web enablement and digital transition of existing services.